BOSTON — In this Healio Video Perspective from Eyecelerator@ASCRS, Matt Link, chief commercial officer of Sight Sciences, shares information on the company’s clinical trials.
“Specifically exciting for us here is the unveiling of two new pieces of clinical evidence, one being the GEMINI 36-month trial that demonstrates clinical efficacy and durability of Omni in the treatment of primary open-angle glaucoma,” Link said. “In addition, we’ll be highlighting our SAHARA data, [a randomized controlled trial] comparing TearCare to the standard of care in the